ImportantMRK
Explain this story: Merck stock after-hours at EUR 127.86: minus 0.41 percent
Explain like I'm 7
Merck's price dropped a tiny bit after the market closed. Merck also agreed to pay a lot of money now, and maybe more later, to work on a new cancer drug.
Partnership · Global license deal for cancer drug SPR2015AD HOC NEWSSector and industry: HealthcareDrug ManufacturersTell me moreShow less
Explain like I'm 7
Merck's price dropped a tiny bit after the market closed. Merck also agreed to pay a lot of money now, and maybe more later, to work on a new cancer drug.
What happenedFrom the article
- Merck & Co. stock traded at EUR 127.86 on October 1, 2026.
- This was a 0.41 percent decrease from its prior close.
- Merck announced a global license agreement with SciBrunch Therapeutics for an investigational cancer drug, SPR2015, including a $400 million upfront payment and potential milestone payments up to $2.13 billion.
- Merck is scheduled to hold its third-quarter 2026 conference call on October 29, 2026.
Why investors careOur explanation
A license agreement lets Merck use another company's drug in exchange for payments. The upfront payment is cash paid right away, while milestone payments are extra money paid later only if the drug hits certain development or sales targets, so they represent possible future costs or